• Patent Title: PARK2 as epigenetic marker for the identification of immune cells, in particular monocytes
  • Application No.: US15752060
    Application Date: 2016-09-22
  • Publication No.: US11761041B2
    Publication Date: 2023-09-19
  • Inventor: Sven Olek
  • Applicant: Precision for Medicine GmbH
  • Applicant Address: DE Berlin
  • Assignee: Precision for Medicine GmbH
  • Current Assignee: Precision for Medicine GmbH
  • Current Assignee Address: DE Berlin
  • Agency: BakerHostetler
  • Priority: GB 16975 2015.09.25
  • International Application: PCT/EP2016/072594 2016.09.22
  • International Announcement: WO2017/050925A 2017.03.30
  • Date entered country: 2018-02-12
  • Main IPC: C12Q1/6881
  • IPC: C12Q1/6881
PARK2 as epigenetic marker for the identification of immune cells, in particular monocytes
Abstract:
The present invention relates to a method, in particular an in vitro method, for identifying monocytes, comprising analyzing the methylation status of at least one CpG position in the mammalian gene region for parkin RBR E3 ubiquitin protein ligase (PARK2), wherein a de-methylation or lack of methylation of said gene region is indicative for a monocyte, when compared to a non-monocyte cell. The analyses according to the invention can identify monocytes on an epigenetic level and distinguish them from all other cells in complex samples, such as, for example, other blood or immune cells. The present invention furthermore provides an improved method for quantifying monocytes, in particular in complex samples. The method can be performed without a step of purifying and/or enriching cells, preferably in whole blood and/or non-trypsinized tissue. Also claimed are kits and specific oligonucleotides for use as primers or probes.
Information query
Patent Agency Ranking
0/0